Biomedical Engineering Reference
In-Depth Information
[114] K. Hermansen and M. Davies, Does insulin detemir have a role in reducing risk of
insulin-associated weight gain?,
Diab. Obes. Metab
., 9, 209-217 (2007).
[115] M. Ellmerer, M. Hamilton-Wessler, S. P. Kim, M. K. Dea, E. Kirkman,
A. Perianayagam, J. Markussen and R. N. Bergman, Mechanism of action in dogs
of slow-acting insulin analog O346,
J. Clin. Endo. Metab
., 88, 2256-2262 (2003).
[116] I. Jonassen, S. Havelund, U. Ribel, A. Plum, M. Loftager, T. Hoeg-Jensen,
A. Volund and J. Markussen, Biochemical and physiological properties of a novel
series of long-acting insulin analogs obtained by acylation with cholic acid deriva-
tives,
Pharm. Res
., 23, 49-55 (2006).
[117] S. Lee, K. Kim, T. S. Kumar, J. Lee, S. K. Kim, D. Y. Lee, Y. K. Lee and Y. Byun,
Synthesis and biological properties of insulin - Deoxycholic acid chemical conju-
gates,
Bioconjugate Chem
., 16, 615-620 (2005).
[118] J. L. Whittingham, I. Jonassen, S. Havelund, S. M. Roberts, E. J. Dodson, C. S. Verma,
A. J. Wilkinson and G. G. Dodson, Crystallographic and solution studies of
N-lithocholyl
insulin:
A
new
generation
of
prolonged-acting
human
insulins,
Biochemistry
, 43, 5987-5995 (2004).
[119] J. Brange and L. Langkjaer, Chemical stability of insulin. 3. Influence of excipients,
formulation, and pH,
Acta Pharm. Nord
., 4, 149-158 (1992).
[120] J. Brange, U. Ribel, J. F. Hansen, G. Dodson, M. T. Hansen, S. Havelund,
S. G. Melberg, F. Norris, K. Norris and L. Snel, Monomeric insulins obtained by
protein engineering and their medical implications,
Nature
, 333, 679-682 (1988).
[121] J. Brange, D. R. Owens, S. Kang and
˚
. Vølund, Monomeric insulins and their
experimental and clinical implications,
Diabetes Care
, 13, 923-954 (1990).
[122] S. Kang, J. Brange, A. Burch,
˚
. Vølund and D. R. Owens, Subcutaneous insulin
absorption explained by insulin's physicochemical properties. Evidence from
absorption studies of soluble human insulin and insulin analogues in humans,
Diabetes Care
, 14, 942-948 (1991).
[123] K. Drejer, The bioactivity of insulin analogues from in vitro receptor binding to in
vivo glucose uptake,
Diabetes Metab. Rev
., 8, 259-285 (1992).
[124] G. Milazzo, L. Sciacca, V. Papa, I. D. Goldfine and R. Vigneri, ASPB10 insulin
induction of increased mitogenic responses and phenotypic changes in human
breast epithelial cells: evidence for enhanced interactions with the insulin-like
growth factor-I receptor,
Mol. Carcin
., 18, 19-25 (1997).
[125] F. G. Hamel, G. L. Siford, J. Fawcett, R. E. Chance, B. H. Frank and W. C. Duckworth,
Differences in the cellular processing of AspB10 human insulin compared with human
insulin and LysB28ProB29 human insulin,
Metab. Clin. Exp
., 48, 611-617 (1999).
[126] K. Drejer, V. Kruse, U. D. Larsen, P. Hougaard, S. Bjørn and S. Gammeltoft, Receptor
binding and tyrosine kinase activation by insulin analogues with extreme affinities
studied in human hepatoma HepG2 cells,
Diabetes
, 40, 1488-1495 (1991).
[127] R. D. DiMarchi, R. E. Chance, H. B. Long, J. E. Shields and L. J. Slieker,
Preparation of an insulin with improved pharmacokinetics relative to human insulin
through consideration of structural homology with insulin-like growth factor I,
Horm. Res
, 41 Suppl. 2, 93-96 (1994).
[128] R. H. Becker, Insulin glulisine complementing basal insulins: A review of structure
and activity,
Diab. Tech. Ther
., 9, 109-121 (2007).
[129] I. Rakatzi, G. Seipke and E. Eckel, [LysB3, GluB29] insulin: a novel insulin analog
with enhanced beta-cell protective action,
Biochem. Biophys. Res. Commun
., 310,
852-859 (2003).
Search WWH ::
Custom Search